Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 28;16(21):3668.
doi: 10.3390/nu16213668.

S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review

Kyrie Eleyson R Baden  1 , Halley McClain  1 , Eliya Craig  1 , Nathan Gibson  1 , Juanita A Draime  1 , Aleda M H Chen  1
Affiliations

S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review

Kyrie Eleyson R Baden et al. Nutrients. .

Abstract

Background/objectives: S-adenosylmethionine (SAMe) is a natural compound implicated in the treatment of liver dysfunction. In this systematic review, our objective was to determine the efficacy, safety, and optimal dose of SAMe in liver diseases.

Methods: Using the PRISMA methodology, we searched PubMed, CINAHL, and Web of Science using key MeSH search terms. For title/abstract screening, full-text review, and data extraction, two independent researchers reviewed articles, and a third researcher resolved conflicts. Data extraction also included a quality assessment of included articles.

Results: Of the 1881 non-duplicated studies, 15 articles focusing on SAMe use in the liver were included. All included studies (n = 15) scored a 4 or 5 out of 5 points on the quality assessment, which indicated high study quality. Overall, SAMe was effective in improving liver-related parameters with few adverse events, which were primarily mild, transient gastrointestinal complaints.

Conclusions: The most common doses were SAMe 1000 mg or 1200 mg per day with or without another treatment or natural supplement. Future studies are needed to assess long-term efficacy and safety data of SAMe and the optimal route of administration in liver diseases.

Keywords: S-adenosylmethionine; SAMe; liver; nutraceutical.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA [12] diagram overviewing study inclusion and exclusion process.
Figure 2
Figure 2
Mechanism of SAMe in liver disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol. 2023;79:516–537. doi: 10.1016/j.jhep.2023.03.017. - DOI - PubMed
    1. Centers for Disease Control and Prevention Chronic Liver Disease and Cirrhosis. [(accessed on 10 September 2024)]; Available online: https://www.cdc.gov/nchs/fastats/liver-disease.htm.
    1. Xu J.Q. Trends in Liver Cancer Mortality Among Adults Aged 25 and over in the United States, 2000–2016. National Center for Health Statistics; Hyattsville, MD, USA: 2018. NCHS Data Brief, no 314.
    1. Riazi K., Azhari H., Charette J.H., Underwood F.E., King J.A., Afshar E.E., Swain M.G., Congly S.E., Kaplan G.G., Shaheen A.A. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2022;7:851–861. doi: 10.1016/S2468-1253(22)00165-0. - DOI - PubMed
    1. Teng M.L., Ng C.H., Huang D.Q., Chan K.E., Tan D.J., Lim W.H., Yang J.D., Tan E., Muthiah M.D. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2023;29:S32–S42. doi: 10.3350/cmh.2022.0365. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources